RE:Some Notes from Last Earnings Conference Call
Lets try this again: (did not format properly last time) - Link at bottom to call: - Optimistic about basic growth drivers in our business - Demographic trends driving Human fertility market, organic growth, new product and service innovation and expanding products thru selective acquisitions will serve us well for many years to come - Seeing market synergies between Instrument business and Embryotech toxicology assay business. Fruits in form of greater exposure, cost savings, and most importantly new business opportunities. In fact, a meaningful order was placed for the Embryotech business from a historical Hamilton Thorne European distributor. - Expand Gynemed branded products to additional international markets and the Americas; Increase European sales of existing Hamilton Thorne instrument business. - 5.2 million US cash position well positioned to invest in growth through acceleration of acquisition program. - Expansion strategy which consists of more sales of Gynemed branded products will enhance overall margins for the Gynemed business. Right now, Gynemed branded products are sold in Europe and select Asian markets. With the Hamilton Thorne distribution lines, will expand to Americas and Asia. - Gynemed - Low hanging fruit right away opportunity to sell to South America where regulatory path is easier. Strong indication that there is business to be had there and waiting day by day for first order. However, dont expect floodgates to open right away. - Integration Very similar to Embryotech. Dont really have to do a hard integration as there is significant level of differentiation between the products and also geographies. More of a financial integration and in maximizing synergies. https://www.hamiltonthorne.com/index.php/earnings-calls/588-q1-2017-conference-call